Biomarker Analysis of Glioblastoma and Potential Implications for Therapy


Joanne Xiu, PhD, Rebecca Feldman-Moreno, PhD, David Arguello, MD, Zoran Gatalica, MD, Anatole Ghazalpour PhD, Ryan P. Bender, PhD, Michael Castro, MD, Sandeep K. Reddy, MD, Gargi D. Basu, PhD, and Les Paul, MD, MS


Glioblastoma multiforme (GBM), the most aggressive CNS cancer, has limited effective therapeutic options, with underlying molecular heterogeneity contributing to the differences in treatment response. Our study was designed to interrogate biomarkers from a large cohort of GBM patients to seek therapeutic implications.

Download Publication